Navidea Biopharmaceuticals announces receipt of notice of award
advertisement

Navidea Biopharmaceuticals announces receipt of notice of award

Press releases may be edited for formatting or style | August 28, 2019 Molecular Imaging
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt of the Notice of Award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (“NIH”) for its Small Business Technology Transfer Phase 1 grant application submitted in collaboration with the University of Alabama at Birmingham (“UAB”), titled “Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques.” The grant award number is R41HL147640 and the award amount is $225,000.

These studies will be done in partnership with Co-Principal Investigator Suzanne Lapi, Ph.D., Professor in the Departments of Radiology and Chemistry and cyclotron facility director at the University of Alabama at Birmingham.

In this grant-supported project, Navidea and UAB will test the hypothesis that Gallium 68 (“Ga68”) tilmanocept CD206-targeted PET imaging of inflammatory macrophages in atherosclerotic plaques will enable direct, noninvasive assessment of the inflammatory microenvironment of plaques. Specifically, Ga68 tilmanocept imaging of atherosclerotic plaques in a relevant mouse model will be performed and comparison made to Fluorine 18 FDG PET imaging. There are currently deficiencies in the state of the art for diagnosing, assessing, and monitoring the efficacies of therapies for atherosclerosis, and a means to reliably and directly assess plaque inflammation by non-invasive imaging is critical to more accurately estimate cardiovascular disease (“CVD”) event risk both in asymptomatic individuals and in CVD patients being treated to prevent a second CVD event. This work will provide fundamental information about the utility of Ga68 tilmanocept for this purpose and will support the clinical work with tilmanocept in atherosclerosis currently running.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

David Ralph, Ph.D., Senior Director of Drug Development for Navidea and Co-Principal Investigator for this project, said, “Activated macrophages are critical contributors to atherosclerosis inflammation. Noninvasive imaging of these macrophages will permit direct assessment of disease processes, likely enabling improved estimates of cardiovascular disease risk for events such as heart attacks.“

Michael Rosol, Chief Medical Officer for Navidea, said, “We are pleased that the NIH continues to recognize the potential of radiolabeled tilmanocept to assess atherosclerosis. This project fits in with our existing atherosclerosis pipeline and will enable us to test tilmanocept as a PET imaging agent and compare it to F18 FDG PET imaging, a widely studied method of looking at macrophages in plaques, but one which we believe has significant deficiencies in comparison to tilmanocept.”


About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.


Source: Navidea Biopharmaceuticals, Inc.

You Must Be Logged In To Post A Comment